Claudio Köser

University of Cambridge

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Microbiology Microbiology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (4)

Wim Mulders

Institute of Tropical Medicine Antwerp

BELGIUM

View details

Bouke de Jong

Head, Mycobacteriology Unit

Instituut voor Tropische Geneeskunde

BELGIUM

View details

Matthias Merker

Assistant Professor

Research Center Borstel - Leibniz Lung Center

GERMANY

View details

Daniela Maria Cirillo

Head of Unit

Ospedale San Raffaele

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Claudio Köser

Research Interests

Explore related searches

Contact this professor

Articles (10)

Quality control and considering systematic MIC shifts are key when evaluating the role of mmpR5 ( Rv0678 ) frameshifts in bedaquiline resistance

All parts of the WHO Mycobacterium tuberculosis mutation catalog need to be applied when evaluating its performance

The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis

Refined understanding of the impact of the <i>Mycobacterium tuberculosis</i> complex diversity on the intrinsic susceptibility to pretomanid.

A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing forMycobacterium tuberculosiscomplex

More nuance and transparency are needed when setting breakpoints for antimicrobial susceptibility testing of pretomanid.

The exceptions that prove the rule—a historical view of bedaquiline susceptibility

Loss-of-function mutations in <i>ndh</i> do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in <i>Mycobacterium tuberculosis</i>

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex.

Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values forMycobacterium tuberculosiscomplex

Collaborators (4)

Wim Mulders

Bouke de Jong

Matthias Merker

Daniela Maria Cirillo

Make your next move.